The Hels-EU project builds on the vision of the Norwegian ICT lighthouse project BIGMED as a basis for defining H2020 applications in areas that needs international collaboration and funding to solve complex clinical and ICT problems and to scale solutions developed in Norway to the international market, in the area of precision medicine. The have had a focus on organizing international consortiums for H2020 funding in four areas:
1. Replicate successful Norwegian demonstrations at international level
2. Scaling of successful demonstrations into products and services for the international market
3. Continue successful Norwegian initiated research to the European level
4. Build collaborations with international groups to build a European lighthouse!
The collaboration between the partners and with other international consortium have led to a realisation of several H2020 applications, summarised hereunder:
Call Topic 1: SC1-BHC-09-2018: Innovation platforms for advanced therapies of the future.
Two partners of the consortium Norwegian Cancer Society and Norway Health Tech have participated in calls together with Norwegian Coordinator Vaccibody AS. The project aimed at first-in-man clinical trial supporting proof of concept to assess efficacy and tolerability of a novel therapeutic platform based on personalized neoepitope cancer vaccines.
Call Topic 2: SC1-BHC-25-2019 - Better health and care, economic growth and sustainable health systems
Stage 1 proposal was submitted in September 2018, with Norwegian participants Norway Health Tech, Oslo University Hospital, DNV and PubGene. The project aims to pilot personalized medicine in R4 EU health systems for successfully treating mental, cardiovascular and autoimmune diseases.
Furthermore, Oslo University Hospital has participated in two H200 calls topics as project partners in collaboration with several partners from Europe:
1. SU-TDS-02-2018: Toolkit for assessing and reducing cyber risks in hospitals and care centres to protect privacy/data/infrastructures
2. SC1-DTH-07-2018: Exploiting the full potential of in-silico medicine research for personalised diagnostics and therapies in cloud-based environments.
During 2019, all partners in consortium have participated in different proposal submitted under H2020 call "SC1-DTH-01-2019: Big data and Artificial Intelligence for monitoring health status and quality of life after the cancer treatment".
- OCC lead has coordinated one international consortium
- NCS has participated in a Norwegian consortium lead by SINET
- NHT together with Innhandet Hospital Trust and SINEF, has participated in a proposal lead by a Spanish consortium
Furthermore, during 2019 the consortium partners have reviewed the H2020 workprogramme for 2020 and have shortlisted a number of call topics which they will either in collaboration or together with other international actors from EU will target in 2020.
The partners have build EU wide H2020 consortium and have applied for several grant proposal during 2018 and 2019.
The detail of these objectives is further elaborated in attachment.
The project will support innovation and collaboration within Norwegian precision medicine value chain stakeholders and by engaging European markets, industrial leaders and R&D providers through exploitation of European funding opportunities. We will facilitate the innovation strategy development in the organisations incorporating integration of European funding/collaboration opportunities as part of their strategy. The network will provide a meeting place and nurture collaboration among stakeholders in the precision medicine value chain, giving rise to new constellations, among the industry, R&D institutes and authorises and end users. Through this effort we will develop EU project ideas leading to establishment of collaboration project proposals submitted to European Commission for funding under H2020, Eurostars and SME Instruments.